Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals

doi:10.3748/wjg.v25.i11.1327

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6255)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

477

WORD

236

HTML

3750

Figures (1-5)

168

Tables (1-4)

145

Sum=4776

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

709

Download

770

Sum=1479

Mar 21, 2019 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Mar 21, 2019; 25(11): 1327-1340
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1327

Table 4 Direct costs by price reduction scenario in billions of euros, disability-adjusted life years and incremental cost-effectiveness ratios

	Base case		HCV elimination strategy
	Base case		Optimistic			Conservative
Years	Direct cost (billion euros)	DALYS	Direct cost (billion euros)	DALYS	ICER (compared to base case)	Direct cost (billion euros)	DALYS	ICER (compared to base case)
2015-2030	1.46	145.920	2.12	80.920	10.100 €	2.33	80.920	13.400 €
2015-2035	1.88	187.470	2.41	84.250	5.100 €	2.74	84.250	8.300 €

HCV: Hepatitis C virus; DALYs: Disability-adjusted life years; ICER: Incremental cost-effectiveness ratio.

Citation: Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World J Gastroenterol 2019; 25(11): 1327-1340
URL: https://www.wjgnet.com/1007-9327/full/v25/i11/1327.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i11.1327